Stay updated on Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page
- CheckyesterdayChange DetectedThe page now displays a 403 Forbidden error, preventing access to the study record. The previously visible trial details and sponsor information are no longer accessible on this page.SummaryDifference21%

- Check8 days agoChange DetectedThe page's revision tag was updated from v3.6.6 to v3.7.0, indicating a new published revision of the study details page.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page now shows revision v3.6.6, replacing the previous v3.6.5. This appears to be a minor backend/CMS patch with no changes to study content or patient-facing information.SummaryDifference0.0%

- Check30 days agoChange DetectedNIH grant/contract funding lines for 2019 and 2023 were added to the study record to reflect the funding sources.SummaryDifference0.1%

- Check44 days agoChange DetectedRevision: v3.6.5 has been added to the page as a new version identifier. The Plain Language Summary and Revision: v3.6.4 have been removed, indicating a small administrative update to the study documentation.SummaryDifference0.1%

- Check51 days agoChange DetectedThe page shows updated and removed date entries (e.g., 2026-07-30, 2026-08-21, 2026-07-28, 2026-07) indicating maintenance timestamps rather than changes to the study content.SummaryDifference0.2%

Stay in the know with updates to Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page.